ImClone C225 Compassionate Use On Hold Pending New Manufacturing Plant
Executive Summary
ImClone Systems will consider restarting a compassionate use program for the epidermal growth factor receptor IMC-C225 when production begins at a newly constructed manufacturing plant, CEO Samuel Waksal, MD, told the House Government Reform Committee June 20.
You may also be interested in...
ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena
The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux
ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena
The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux
Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?
Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.